Adynovate Is An Extended Half-Life Recombinant Factor Viii (Rfviii) Treatment, Using Established Technology (Controlled Pegylation), For Hemophilia A Patients. This Option Offers Lower Weekly Infusion Rates Than Standard Fviii, Providing Excellent Prophylactic Coverage. Takeda Pharma Has Expanded Its Innovative Rare Diseases Portfolio In India With The Launch Of Adynovate, An Innovative Extended Half-Life Recombinant Factor Viii (Rfviii) Treatment, Using Established Technology (Controlled Pegylation), For Haemophilia A Patients, A Company Statement Said. It Also Said That Adynovate, In Combination With Mypkfit, The First And Only Fdaapproved Application, Offers Personalised And Interactive Prophylaxis Treatment Option That Enables Both Healthcare Professionals And Patients In Real-Time Monitoring Of Factor Viii Levels From The Comfort Of Their Homes On Phone Thereby Adapting Their Activity Decisions Accordingly And Help Improve Their Quality Of Life. Alerts Are Sent To Patients On Prophylaxis When Their Estimated Factor Viii Levels Are Low, And Reminds Them When Their Infusions Are Due, Thereby Providing Excellent Prophylactic Coverage. Administered In Three Steps With The Baxject Iii System, Adynovate Eliminates The Need To Disinfect The Vial, As Vials Are Already Assembled In The System Housing. It Can Be Stored At Room Temperature Not To Exceed 30
